Companies · Biotechnology
MENLO PARK · Biotechnology
Diligence memoA one-page analyst read on BIO-NEMS Corp — recommendation, valuation, rhythm, risks.→BIO-NEMS Corp looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
BIO-NEMS Corp is one of 4291 Biotechnology companies tracked from MENLO PARK. By capital raised it ranks in the long tail (ahead of 24% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 24% of sector peers (real $). Modeled value above 19% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #121 of 152.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Cerebral Magnetics INC | Pre-Seed | $1.0M | $55.2M | 2.61× |
| AnTolRx, Inc. | Pre-Seed | $1.0M | $55.2M | 2.61× |
| NutriBand Inc. | Pre-Seed | $1.2M | $55.2M | 2.61× |
| US Biologic, Inc. | Pre-Seed | $1.0M | $55.2M | 2.61× |
| New Vital Signs, Inc. | Pre-Seed | $1.0M | $55.2M | 2.61× |
| Jivana Biotechnology Inc | Pre-Seed | $2.0M | $55.2M | 2.61× |
| Zeta Biolongevity, Inc. | Pre-Seed | $995K | $54.9M | 2.60× |
| ALRGN Bio, Inc. | Pre-Seed | $946K | $52.2M | 2.47× |
| BioSurfaces, LLC | Pre-Seed | $900K | $49.7M | 2.35× |
| Cellsolutions Llc | Pre-Seed | $1.9M | $49.7M | 2.35× |
| Pique Therapeutics, Inc. | Pre-Seed | $1.4M | $47.2M | 2.23× |
| NeuExCell Therapeutics Inc. | Pre-Seed | $850K | $46.9M | 2.22× |
| BIO-NEMS Corp this company | Pre-Seed | $1.5M | $10.0M | 0.47× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $725K | 2012-11-05 | $4.0M | $40.0M | 85% |
| Pre-Seed | $200K | 2013-12-05 | $1.1M | $11.0M | 85% |
| Pre-Seed | $100K | 2013-12-05 | $556K | $5.5M | 85% |
| Pre-Seed | $414K | 2015-10-19 | $2.3M | $22.9M | 85% |
| Pre-Seed | $182K | 2016-12-19 | $1.0M | $10.0M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Paul Russo | — | 3 other | 2016-12 |
| Leslie L. Vadasz | — | 2 other | 2013-12 |
| Regis McKenna | — | 2 other | 2016-12 |
| Paul L. Russo | — | 1 other | 2015-10 |
| David Medin | — | — | 2012-11 |
| Jaleh Daie | — | — | 2016-12 |
| Jim Russ Moniz | — | — | 2012-11 |
| Regis L. McKenna | — | — | 2015-10 |
| S Russ Lehrman | — | — | 2012-11 |
BIO-NEMS Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| OrthoFundamentals, LLC | Biotechnology | Pre-Seed | $1.5M | $7.0M | same sector · same stage |
| AvanSci Bio, L.L.C. | Biotechnology | Pre-Seed | $1.5M | $8.8M | same sector · same stage |
| Arrevus, Inc. | Biotechnology | Pre-Seed | $1.4M | $8.3M | same sector · same stage |
| PolyPlexx, LLC | Biotechnology | Pre-Seed | $1.4M | $11.4M | same sector · same stage |
| Avenzoar Pharmaceuticals, Inc. | Biotechnology | Pre-Seed | $1.4M | $8.1M | same sector · same stage |
| Sarcio, Inc. | Biotechnology | Pre-Seed | $1.4M | $13.4M | same sector · same stage |
| Cypris Medical, Inc. | Biotechnology | Pre-Seed | $1.7M | $8.3M | same sector · same stage |
| Endonovo Therapeutics, Inc. | Biotechnology | Pre-Seed | $1.7M | $12.4M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Nexsis Biosciences LLC | Biotechnology | Pre-Seed | $16.0M | 90% |
| NE1 Inc. | Biotechnology | Seed | $29.2M | 88% |
| NERx Biosciences, Inc. | Biotechnology | Pre-Seed | $4.8M | 87% |
| Neuros Medical, Inc. | Biotechnology | Series C | $338.1M | 87% |
| NemaMetrix Inc. | Biotechnology | Series A | $186.6M | 87% |
| Nexeon Medsystems Inc | Biotechnology | Series B | $46.2M | 87% |
| NGM Bio Holdings, Inc. | Biotechnology | Series C | $649.8M | 86% |
| ARTMS Inc. | Biotechnology | Series A | $174.7M | 86% |
See where BIO-NEMS Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at BIO-NEMS Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.